Double-blind comparative trial of trimethoprim/sulfamethopyrazine once daily vs erythromycin 4 X daily in patients with ENT infections.
Forty-two patients suffering from acute or recurrent ENT infections were given either 250 mg erythromycin 4 X daily or a new sulfamethopyrazine/trimethoprim combination (200 + 250 mg) once daily after a double loading dose on the 1st day, for 12 days on the average. Otitis media and externa, perichondritis, maxillary and frontal sinusitis were the most frequent clinical pictures. Assessment of efficacy was based on the course of objective and subjective clinical symptoms and, whenever possible, on bacteriologic findings. The new sulfa-trimethoprim combination showed activity similar to the reference drug, but it may have the advantage of a simpler dosage schedule.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D004917:Erythromycin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D013420:Sulfamethoxazole / Q000008:administration & dosage* / Q000627:therapeutic use; D014295:Trimethoprim / Q000008:administration & dosage* / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D004917:Erythromycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole